Your browser doesn't support javascript.
Systemic immunosuppression in times of COVID-19: Do we need to rethink our standards?
Grabbe, Stephan; Beissert, Stefan; Enk, Alexander.
  • Grabbe S; Department of Dermatology, Johannes Gutenberg University, Mainz, Germany.
  • Beissert S; Department of Dermatology, University Hospital Carl Gustav Carus, Technical University of Dresden, Dresden, Germany.
  • Enk A; Department of Dermatology, University Hospital of the Ruprecht-Karls-University, Heidelberg, Germany.
J Dtsch Dermatol Ges ; 18(8): 810-813, 2020 08.
Article in English | MEDLINE | ID: covidwho-693539
ABSTRACT
The current SARS-CoV-2 pandemic particularly endangers older people with pre-existing cardiopulmonary and metabolic conditions. However, it is also currently under discussion whether patients under immunosuppressive therapy also have a higher risk of suffering a severe course of the COVID-19 disease. In principle though, there is currently no data available for a general reduction or pause of immunosuppression in patients with autoimmune diseases because of the SARS-CoV-2 pandemic. However, since there is currently neither an effective therapy nor corresponding vaccination protection, the indication for a prolonged immunosuppressive therapy should be made with special care. In particular, immunotherapeutic agents that produce long-term effects (e.g., rituximab) should be used with special caution. In contrast, immunomodulating substances that do not suppress antiviral immunity (e.g. systemic immunoglobulins, doxycycline), or that have intrinsic effects on SARS-CoV-2 (calcineurin inhibitors, chloroquine, hydroxychloroquine) may be useful alternatives.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Immunosuppression Therapy / COVID-19 Drug Treatment Type of study: Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: J Dtsch Dermatol Ges Journal subject: Dermatology Year: 2020 Document Type: Article Affiliation country: Ddg.14194

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Immunosuppression Therapy / COVID-19 Drug Treatment Type of study: Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: J Dtsch Dermatol Ges Journal subject: Dermatology Year: 2020 Document Type: Article Affiliation country: Ddg.14194